Medical News Today (MNT)GLP-1s Don’t Work for Everyone: Why, and What to Do?

GLP‑1 receptor agonists have become a cornerstone of obesity and metabolic disease management. Although many patients experience meaningful weight loss, a substantial subset has little or no response, highlighting the growing need to understand treatment variability and alternative strategies.

These findings reflect emerging research and expert synthesis. They do not establish standardized combination protocols, but they reinforce that obesity treatment requires individualized, multi‑pathway approaches.

Key Clinical Insights

• Up to 20% of patients may experience minimal weight loss on GLP‑1 therapy alone.
• Genetic variation may partly explain differences in response to GLP‑1 medications.
• A recent review suggests that combining GLP‑1 therapy with naltrexone‑bupropion (NB‑ER) may benefit some non‑responders by targeting both satiety and food‑reward pathways.
• GLP‑1s primarily reduce hunger and promote early satiety, while NB‑ER influences cravings and hedonic eating behaviors.

Broader Clinical Considerations

• Obesity is increasingly understood as biologically heterogeneous, with hormonal, genetic, neurologic, and behavioral contributors.
• Poor response does not imply nonadherence or lack of effort, and expectation management is critical.
• Combination pharmacotherapy may represent one avenue toward personalized obesity care, though further study is needed.

Clinical Relevance Across Specialties

• Reinforces that GLP‑1 therapy is not one‑size‑fits‑all
• Supports individualized discussions when patients are frustrated by limited response
• Highlights emerging interest in combination strategies, without implying immediate practice change
• Encourages clinicians to reassess treatment goals, mechanisms, and patient‑specific drivers of obesity

More on GLP-1s